Discover
SER
Serina Therapeutics, Inc.
2.69
1 x 2.70
1 x 2.80
bid
ask
+
0.02
0.75%
12:34 PM
timesize
| Ytd | 40.84% | |
| 1y | -47.25% |
2.68
day range
2.83
1.22
52 week range
7.92
| Open | 2.69 | Prev Close | 2.67 | Low | 2.68 | High | 2.83 | Mkt Cap | 40.34M |
| Vol | 92.98K | Avg Vol | 86.25K | EPS | -2.00 | P/E | -1.34 | Forward P/E | N/A |
| Beta | 1.11 | Short Ratio | 1.96 | Inst. Own | 3.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 2.01 | 200-d Avg | 2.46 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 6.28M | ||
| Research and Development Expense | 3.20M | ||
| Selling, General and Administrative Expense | 3.08M | ||
| Operating Income | -6.28M | ||
| Interest Expense | 189.00K | ||
| Income Tax Expense | 7.00K | ||
| Net Income | -6.90M | ||
| Net Income Common Stock | -6.93M | ||
| Net Income Common Stock (USD) | -6.93M | ||
| Consolidated Income | -6.90M | ||
| Earnings per Basic Share | -0.58 | ||
| Earnings per Basic Share (USD) | -0.58 | ||
| Earnings per Diluted Share | -0.58 | ||
| Earning Before Interest & Taxes (EBIT) | -6.70M | ||
| Earning Before Interest & Taxes (USD) | -6.70M | ||
| Preferred Dividends Income Statement Impact | 37.00K | ||
| Weighted Average Shares | 12.05M | ||
| Weighted Average Shares Diluted | 12.05M | ||
| Balance Sheet | |||
| Cash and Equivalents | 24.53M | ||
| Cash and Equivalents (USD) | 24.53M | ||
| Current Assets | 26.47M | ||
| Property, Plant & Equipment Net | 800.00K | ||
| Total Assets | 27.30M | ||
| Total Debt | 3.17M | ||
| Current Liabilities | 6.34M | ||
| Debt Non-Current | 3.17M | ||
| Total Liabilities | 9.67M | ||
| Accumulated Retained Earnings (Deficit) | -70.40M | ||
| Accumulated Other Comprehensive Income | -8.00K | ||
| Shareholders Equity | 17.63M | ||
| Shareholders Equity (USD) | 17.63M | ||
| Assets Non-Current | 825.00K | ||
| Total Debt (USD) | 3.17M | ||
| Liabilities Non-Current | 3.33M | ||
| Trade and Non-Trade Payables | 2.83M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 74.00K | ||
| Net Cash Flow from Financing | 26.06M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 21.47M | ||
| Capital Expenditure | -25.00K | ||
| Issuance (Purchase) of Equity Shares | 26.06M | ||
| Net Cash Flow from Investing | -25.00K | ||
| Net Cash Flow from Operations | -4.57M | ||
| Effect of Exchange Rate Changes on Cash | 6.00K | ||
| Share Based Compensation | 1.08M | ||